Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety Comparison of DWJ1525 vs Co-administration of DWP16001 and DWC202101 in Healthy Volunteers
NCT05192395Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and Maximum Plasma Concentration. Started Apr 2022; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05192395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192395.